Pichia pastoris (syn. Komagataella phaffii), a methylotrophic yeast, is a proven platform for pharmaceutical protein production. However, its potential reaches far beyond. As a reliable, scalable, and cost-efficient platform for recombinant protein expression, Pichia is equally suited for industrial enzymes, food & feed, diagnostics, and biomaterials.
Sino Biological Sets New Industry Standard with ProPure™ Endotoxin-Free Proteins
Sponsored PublicationsSino Biological US, Inc. proudly unveils ProPure™, an industry-leading line of ultra-pure, endotoxin-free recombinant proteins, fully produced in the USA at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas.
UK Food Standards Agency accepts Gourmey’s application for cultivated Foie Gras
Latest NewsThe British Food Standards Agency (FSA) has formally accepted an application by French start-up Gourmey SAS for regulatory approval of its cultivated foie gras, a product developed using cellular agriculture techniques. The submission was initially lodged on 26 July 2024 and was made in parallel across five jurisdictions: the European Union, United States, Singapore, Switzerland, and the United Kingdom.
First step towards scaling chemical production from CO₂
Latest NewsAs part of the green transformation of North Rhine-Westphalia’s former coal-mining region, independent assessors have recommended the co-financing of two biotechnology processes developed at pilot scale by Evonik Industries AG, with the aim of advancing them to demonstration scale. The third funding round of the “Produktives.NRW” call includes approximately €70 million from the EU’s Just Transition Fund (JTF) allocated to six projects.
Nuclidium fuels next radiopharma wave
Latest NewsBasel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group.
Actithera: Radiopharma Funding Gathers Huge Momentum
Latest NewsThe biotech company Actithera, with locations in Cambridge, USA, and Oslo, Norway, has successfully closed a major Series A round, raising US $75.5 million. Its isotope-agnostic platform — designed with a specific focus on the interaction between linker and target molecule — has attracted strong interest from a wide range of investors. However, the path to this achievement was not as straightforward as anticipated, CEO Andreas Goutopoulos told European Biotech News.
Ciloa SAS secures €6.5m to advance lead candidate APN-sEV into clinical development
Latest NewsFrench biotech Ciloa SAS has received a €6.5m grant to advance its adiponectin-loaded exosome candidate, APN-sEV, into Phase I safety trials, ahead of efficacy evaluation in indications including type 2 diabetes, obesity, and liver fibrosis.
Solar Foods continues expansion in the US
Latest NewsAfter Finnish protein powder producer Solarfoods signed a strategic agreement with two US food manufacturers to supply 6,000 tonnes of Solein from 2030 onwards, the company has now announced a more concrete partnership with US flavour manufacturer Sensapure Flavours Inc.
Enzymatica CEO steps down
AppointmentsThe CEO of Lund-based Enzymatica AB, Claus Egstrand, is stepping down from his role. CFO Therese Filmersson will also leave her position. The process of finding their successors has already begun.
Unlocking Pichia for industry
BackgroundPichia pastoris (syn. Komagataella phaffii), a methylotrophic yeast, is a proven platform for pharmaceutical protein production. However, its potential reaches far beyond. As a reliable, scalable, and cost-efficient platform for recombinant protein expression, Pichia is equally suited for industrial enzymes, food & feed, diagnostics, and biomaterials.
IZB-Start-up ions.bio
Sponsored PublicationsIions.bio was founded in 2024 and is located in the Innovation and Startup Centre IZB in Planegg-Martinsried.